home / stock / tffp / tffp quote
Last: | $ |
---|---|
Change Percent: | -1.01% |
Open: | $5.10 |
Close: | $5.02 |
High: | $5.10 |
Low: | $5.01 |
Volume: | 7,787 |
Last Trade Date Time: | 02/12/2020 04:43:40 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $5.10 | $5.02 | $5.10 | $5.01 | 7,787 | 02-12-2020 |
$ | $5.05 | $5.0711 | $5.10 | $5.01 | 22,063 | 02-11-2020 |
$ | $5.01 | $5.0583 | $5.0583 | $5.01 | 5,195 | 02-10-2020 |
$ | $5.0433 | $5.055 | $5.0803 | $5.03 | 12,889 | 02-07-2020 |
$ | $5.037 | $5.00 | $5.073 | $4.9009 | 14,014 | 02-06-2020 |
$ | $5.0628 | $5.065 | $5.0964 | $5.05 | 10,187 | 02-05-2020 |
$ | $5.0535 | $5.0627 | $5.125 | $5.05 | 18,768 | 02-04-2020 |
$ | $5.21 | $5.15 | $5.2941 | $5.12 | 27,100 | 02-03-2020 |
$ | $5.24 | $5.25 | $5.30 | $5.05 | 47,018 | 01-31-2020 |
$ | $5.2001 | $5.2185 | $5.25 | $5.2001 | 6,090 | 01-30-2020 |
$ | $5.35 | $5.20 | $5.3799 | $5.20 | 48,195 | 01-29-2020 |
$ | $5.1642 | $5.36 | $5.60 | $5.12 | 114,757 | 01-28-2020 |
$ | $5.105 | $5.02 | $5.18 | $5.02 | 5,129 | 01-27-2020 |
$ | $5.12 | $5.0724 | $5.12 | $5.0724 | 1,882 | 01-24-2020 |
$ | $5.10 | $5.18 | $5.24 | $5.09 | 23,433 | 01-23-2020 |
$ | $5.1101 | $5.15 | $5.15 | $5.10 | 16,421 | 01-22-2020 |
$ | $5.20 | $5.12 | $5.20 | $5.10 | 12,658 | 01-21-2020 |
$ | $5.22 | $5.20 | $5.28 | $5.1501 | 17,312 | 01-20-2020 |
$ | $5.22 | $5.20 | $5.28 | $5.1501 | 17,312 | 01-17-2020 |
$ | $5.28 | $5.25 | $5.28 | $5.10 | 9,626 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
TFF Pharmaceuticals Inc - Ordinary Shares Company Name:
TFFP Stock Symbol:
NYSE Market:
The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models ...
FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thi...
Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional patients ha...